@article{oai:nagasaki-u.repo.nii.ac.jp:00012507,
 author = {山本, 善裕 and 柳原, 克紀 and 栗原, 慎太郎 and 中村, 茂樹 and 関, 雅文 and 泉川, 公一 and 掛屋, 弘 and 河野, 茂 and Nagasaki, Respiratory tract infection Treatment Society  NRTS},
 issue = {6},
 journal = {日本化学療法学会雑誌, Japanese Journal of Chemotherapy},
 month = {Nov},
 note = {今回，65歳以上の慢性呼吸器疾患の二次感染に対するgatifloxacin（GFLX）1回100 mg，1日2回投与の有用性を客観的に検証するため，同じニューキノロン系抗菌薬であるlevofloxacin（LVFX）を対照薬として有用性を比較検討した。　2006年1月から2007年4月の間に，長崎大学第二内科および関連病院を受診した，65歳以上の慢性呼吸器疾患の二次感染患者72例を対象とし，GFLX 1回100 mg，1日2回投与群，LVFX 1回200 mg，1日2回投与群の2群に無作為に割付を行った。投与期間は7日間とした。　本試験の対象72例中，臨床効果解析対象60例（GFLX群；33例，LVFX群；27例）における有効率は，GFLX群78.8％（26/33），LVFX群70.4％（19/27）であった。副作用については両群とも認められず，臨床検査値異常がGFLX群4例において認められたがいずれも重篤なものではなかった。　65歳以上の高齢者慢性呼吸器疾患の二次感染に対して，GFLXの1回100 mg，1日2回投与は，LVFX 1回200 mg，1日2回投与と同等もしくは同等以上の有用性を示すことが示唆された。, From November, 2004 to March 2005, we found that gatifloxacin(GFLX) doses of 100 mg b.i.d. (200 mg/day) for the treatment of secondary infections in senior citizens (age?65 years) with chronic respiratory illness were as safe and effective as doses of 200 mg b.i.d. (400 mg/day) in non senior citizens. A controlled study was conducted to evaluate the efficacy of GFLX doses of 100 mg b.i.d. in senior patients with chronic respiratory tract infections using levofloxacin(LVFX), a new quinolone antimicrobial drug, as the control drug. We randomly distributed GFLX doses of 100 mg b.i.d. or LFLX doses of 200 mg b.i.d. to 72 patients (age?65) with chronic respiratory tract infections between December 2005 and April 2007. Medications were administered to patients for 7 days. We evaluated 60 patients (GFLX group: 33, LVFX group: 27) for the efficacy of medications, 70 patients (GFLX group: 36, LVFX group: 34) for side effects, and 65 (GFLX group: 35, LVFX group: 30) for abnormal laboratory results from a total of 72 patients. Clinical efficacy was 78.8% (26/33) in the GFLX group and 70.4% (19/27) in the LVFX group. Side effects were not observed in either group, and abnormal laboratory results were observed in 4 patients in the GFLX group. These abnormal laboratory results were generally mild in nature. Our results suggest that GFLX doses of 100 mg b.i.d. are as effective as or more effective than LVFX doses of 200 mg b.i.d. for the treatment of secondary infections resulting from chronic respiratory diseases in senior citizens., 日本化学療法学会雑誌, 55(6), pp.441-450; 2007},
 pages = {441--450},
 title = {高齢者慢性呼吸器疾患の二次感染に対するgatifloxacinとlevofloxacinの7日間投与の比較試験},
 volume = {55},
 year = {2007}
}